Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis.

Crit Care · 2025 · PMC12896118 · PMID 41444652

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

borderline significantP = 0.05actually significant

A prior meta-analysis also revealed a borderline significant lower risk of in-hospital mortality when compared with NA under random-effect model (RR: 0.79, 95%CI: 0.63–1.00, P = 0.05) [ 41 ].

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.